Home > Boards > US OTC > Biotechs >

NorthWest Biotherapeutics Inc. (NWBO)

NWBO RSS Feed
Add NWBO Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Astavakra, sentiment_stocks, Know-Fear, HappyLibrarian, jammyjames
Search This Board: 
Last Post: 5/19/2019 2:06:39 AM - Followers: 660 - Board type: Free - Posts Today: 7







 Stylized Dendritic Cell featured on NWBO board since 2015

Ad from GoBoldly PhRMA Ad Campaign - 2017


"The UCLA Brain Tumor Program continues to shine as a beacon of hope, carrying a record of
patients with brain tumors living longer than patients treated at any other hospital.  
Our personalized brain cancer vaccine, DCVax, is the first of its kind and is currently in
Phase III clinical trials in 46 centers throughout America.  
It is on the road to FDA approval as well as clinical trials throughout Europe.  
Using this vaccine, we are harnessing the patient's immune system, genetics, pathology, brain mapping
and a wide database of bioinformatics to optimize outcomes."

- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA

 


Abstracts
"Clinical and immunopathological effects following Image-guided intratumoral injection of activated, autologous dendritic cells in patients with advanced solid cancers" - Abstract #2499 - AACR (American Association for Cancer Research)
"Proffered Paper:  Prolonged Survival for Patients with Recurrent Glioblastoma Multiforme who are Treated with Tumor Lysate-Pulsed Autologous Dendritic Cells" - presented at ITOC-Conference, Munich, Germany - March 26, 2015, 14:40 - Marnix Bosch, Chief Technical Officer, NW Bio (note, abstract linked here is from Science Direct)

Annual Share Holder Meetings

Answer Notes from shareholder questions - supplied by IkeEsquire i-hub post #212334 - 2/3/19

NWBO Board of Directors
Cofer Black, Independent Director
Alton L. Boynton, Chief Scientific Officer, Secretary and Director
Jerry Jasinowski, Independent Director
Navid Malik, Independent Director
Linda F. Powers, Chairman of the Board, President, CEO and CFO


NWBO Investor Relations Contact Person
David "Dave" Innes, Investor Relations
email:  dinnes@nwbio.com
Cell:  (804) 513-4758

Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind) 
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator:  Mayo Clinic

Company Contact Info
Investor Relations:
Les Goldman  (Company)     (202) 841-7909  lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)

Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814  (240) 497-9024

Corporate Profile

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.  NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.

Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer.  This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.

Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.  

 They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

DCVAX Survival Stories
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
NWBO GBM Brain Cancer Suvivial Story of Brad Silver
NWBO, GBM Brain Cancer Survival Story of Mike Gregoire
UCLA - Real Stories Using DCVax

DCVax-Direct Patent and Survival Stats - provided by i-hub NWBO long - abeta
Click here to be taken to pos #217560 with larger image



Designations & Awards
German Hospital Exemption (referred to as HE) Information for DCVax-L® - FIRST TIME EVER

DCVax-L Hospital Exemption Program Now Under Way in Germany (NWBO, PR Newswire, October 14, 2014)
Two German Approvals:  "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement (NWBO, March 10 2104)
Analysis:  NWBO DCVax-L German Approval Under Hospital Exemption Early Access Program (Smith on Stocks, Nasdaq, March 11, 2014)
Exclusive - Germany OKs Northwest Bio Brain Cancer Drug, Shares Soar (Ransdell Pierson, Reuters, March 10, 2014)

Fails-to-Deliver Data with the SEC
Data downloads

FINRA-Reg SHO Daily Files
Reported short sale trade data

FDA Endpoints & Approval Information
House committee approves bill to speed new drugs to market - May 21, 2015 (Toni Clarke, Reuters)
FDA could approve drugs fro new uses on less data:  draft law - April 29, 2015 (Toni Clarke, Reuters)
Richard Pazdur says FDA racing approvals due to unprecedented efficacy - April 15, 2015 (BioCentury TV)

Glioblastoma Subtypes


source:  Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach - February 2018

United Kingdom Awards DC-Vax-L® as Promising Innovative Medicine (PIM) - FIRST TIME EVER
First UK "Promisting Innovative Medicine" Designation Awarded (Department of Health and George Freeman MP, Gov.UK, September 16, 2014)
NWBO's Cancer Vaccine is the First Drug to be Designated by UK Authorities as a "Promising Innovative Medicine" (PIM) - (NWBO, September 16, 2014)

Interviews
Linda Powers Interview 5-15-12

Important or Helpful Links
NWBO Stock Quote & Information
NWBO SEC Filings
NWBO Twitter
NWBO Facebook
NWBO Yahoo Message Board

Upcoming Healthcare Conferences

Institutional Investments
Nearing "the finish line" on cancer vaccine trial, Maryland firm raises $40 million - April 3, 2015 (J.D. Harrison)
Northwest Biotherapeutics:  The $40 Million Woodford Financing is A Major Positive - April 3, 2105 (Smith on Stocks - Larry Smith)


Journal Articles
Journal of Translational Medicine
- May 29, 2018 / Open access
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Linda Liau - Principal Investigator for DCVax-L P3 Trial
12/19/16 Email to shareholder

Market Cap Potential with GBM And Sales Multiples - Comparison to Optune
Chart compiled by long share holder and ihub poster abeta


NWBO Analysis
Northwest Biotherapeutics:  Revised Modeling Based on New Blended Data is Encouraging - June 14, 2018 (Seeking Alpha - Leprecon777)
Dendritic Vaccine for Glioblastoma:  Hope Hyped, Say Some - June 13, 2018 (Medscape - Alexander M. Castellino)

BBC 6:00 p.m. News - May 29, 2018 - click on video in tweet
Northwest Bio's Big Data Change the Game - June 3, 2018 (Zach Hartman)

DCVax-L:  A Reimbursement Perspective - November 22, 2014 (Seeking Alpha - Ryan Pawell)
DCVax-Direct Validation and Updated DCVax-L Ph III Modeling - November 6, 2014 (Seeking Alpha - Steven Giardino [Pyrr])
Now is the Time for Northwest Biotherapeutics - October 29, 2014 (Seeking Alpha - Steven Giardino (Pyrr)


NWBO News
NWBO Press Releases 
NWBO Yahoo Headlines

NWBO Older News
NWBO Receives Approval for US Patent for Cost Saving Automation of High-Concentration DCVax Manufacturing - Already cleared by FDA for use in Clnical Trials
- December 4, 2009

NWBO - Short Seller Rebuttals and Information
Washington Post - Pulitzer Prize Winning Steven Pearlstein addresses NWBO and Short Selling
Citizens for Responsibility and Ethics in Washington (CREW) Requests SEC Investigate Manipulation of Drug Company Stock Price to Benefit Short Sellers
My Dialogue with Adam Feuerstein on Northwest Biotherapeutics - September 25, 2014 (Larry Smith, Smith on Stocks)
Jim Cramer Explains How the Stock Market is Manipulated - sounds a bit like some of the techniques used here.


Recent Past Presentations
Cancer Vaccines and Neoantigens - Marnix L. Bosch, CTO - August 31, 2017 - Slides
ASCO 2017 - Update on Clinical Programs - Marnix L. Bosch, CTO - Slides - June 5, 2017

Patent Information
Espacenet Patent information for NWBO
Patentdocs - Patent applications for NWBO
JUSTIA Patents
NWBO Receives U.S. Patent on Broad Processes for Producing More Potent Dendritic Cells - March 18, 2013 
NWBO's Patent Portfolio is Further Expanded with Manufacturing Automation Patent - September 10, 2013
NWBO Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax Manufacturing - December 4, 2009
NWBO - Wikiinvest Intellectual Property - from the 10-K filed April 15, 2008

Patient Info
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer

Presentations
"Developments in Neurosurgery for brain tumors" - by UK/Europe Primary Investigator - King's College Hospital (UK) Professor Keyoumars Ashkan (see minute 8:18) - Published 7-18-17 by The Brain Tumour Charity
"Advances in Glioblastoma Treatment" - by Colorado Primary Investigator - Boulder Neurosurgical Associates - Michael Pearlman, M.D. (see minute 19:10) - Published November 22, 2015

Press Coverage - Recent
Brain Cancer Vaccine Moves Closer to Reality During Clinical Trial - Ann Pietrangelo (Health Line - June 13, 2018
New Vaccine for Aggressive Brain Cancer Shows Promising Results - 91.7 WVXU 88.5 WMUB, Cincinnati, Oxford - June 6, 2018
Personalized vaccine may increase long-term survival in people with the deadliest form of brain cancer - UCLA Newsroom - June 5, 2018
New approach to treating glioblastoma could add years to patients' lives - New York Daily News - June 5, 2018
Personalized Vaccine Effective in Some Glioblastoma Patients - Sci News - June 4, 2018 
Brain Cancer Vaccine Could Boost Incurable Glioblastoma Survival from Months to Years - Newsweek - May 31, 2018
Scientists created a brain-cancer vaccine - and so far it's 'remarkably promising' - Miami Herald - May 30, 2018
Researchers buoyed by brain cancer trial - The Australian - May 30, 2018

Press Coverage - UK News Coverage
Outcomes of immunotherapy vaccine trial show encouraging results for glioblastoma patients - Brain Tumour Research - May 30, 2018
Brain cancer vaccine could give years of extra life to patients like Dame Tessa Jowelll, finds trial - Independent - May 30, 2018
Brain cancer could extend lives of patients by years - Belfast Telegraph - May 29, 2018
Vaccine for cancer that killed Tessa Jowell 'remarkably promising' - BBC News - May 29, 2018
Brain cancer vaccine could extend lives of patients by years - The Guardian (UK) - May 29, 2018
Cancer Treatments - Supplement in United Kingdom Times April 6, 2015
NW Bio Announces $40 Million Financing - Further Equity by Woodford Funds April 2, 2015
Woodford's new biotech could be the next Amgen November 26, 2014 (Gavin Lumsden, Citywire Money)
Neil Woodford invests £16m in brain cancer vaccine company November 19, 2014 (Ashley Armstrong, The Telegraph)

Reports
Orphan Drug Report 2014  (EvaluatePharma, October 2014 - see page 14 ) 

Research Posters
AARC April 2015 - Prolonged Survival in Patients with Recurrent Glioblastoma Multiforme Who are Treated with Tumor Lysate-Pulsed Autologous Dendritic Cells
AARC April 2015 - Clinical and Immunopathological Effects Following Image-guided Intratumoral Injection of Activated, Autologous Dendritic Cells in Patients with Advanced Solid Cancers
SITC 2014 - Direct
ASCO 2014 - Direct

Scientific Advisory Board
Dr. Mac Cheever - Fred Hutchison Cancer Research Center (FHCRC), Professor of Medicine and Director of NCI-funded Cancer Immunotherapy Trials Network (CITN)
Dr. Alfredo Quinoones-Hinojosa - William J. and CharlesH. Mayo Professor, Chair of Neurologic Sugery, Mayo Clinic in Jacksonville, FL, 
Dr. Jerome Galon - French Biologist, Ph.D. in Immunology, Cordeliers Research Center, Director of the INSERM Laboratory Integrative Cancer Immunology
Dr. Samir N. Khleif - Director of the GRU Cancer Center, Augusta, GA
Dr. John Smyth - Professor Emeritus Medical Oncology and Honorary Assistant Principal Cancer Research Development
Scientific Advisory Board PR Announcement: - June 13, 2016

Sawston Location
US Biotechnology Company Doses Upon Space in Cambridge - link is to i-hub post with story.  Actual story requires sign up.

SEC Reports
Form 10-Q for fiscal 3rd Quarter ending September 30, 2018
Form 10-Q for fiscal 2nd Quarter ending June 30, 2018
Form 10-Q for fiscal 1st Quarter ending March 31, 2018
Form 10-K - for fiscal year ending December 31, 2017
Form 10-Q - for fiscal 3rd Quarter ending September 30, 2017
Form 10-Q - for fiscal 2nd Quarter ending June 30, 2017
Form 10-Q - for fiscal 1st Quarter ending March 31, 2017
Form 10-K - for fiscal year ending December 31, 2016
Form 10-Q - For fiscal 3rd Quarter ending September 30, 2016
Form 10-Q - for Fiscal 2nd Quarter ending June 30, 2016
Form 10-Q- for Fiscal 1st Quarter ending March 31, 2016
Form 10-K - For fiscal year ended December 31, 2015

Short Report
OTC - FINRA - Equity Short Interest

Standard of Care (SOC) Stupp Survival Figures from 2005 Study


Stock Quote & Summary
As of September 7, 2018 - approximate and subject to verification 


Common Shares Outstanding:  444,600,000

Potentially Dilutive Securities:   
Series A convertible preferred stock:  32,187,000
Series B convertible preferred stock:  75,059,000
Common stock options:  97,192,000
Common stock warrants - liability treatment:  356,844,000
Contingently issuable warrants:  11,739,000
Share-Settled debt and accrued interest, at fair value:  11,046,000
Convertible notes and accrued interest:  40,923,000

Potentially dilutive shares:       624,990,000

 Source:  6/30/18 10Q


Inside Ownership of NWBO Common Stock held (4-17-18): 

Security Holder  - Linda Powers, CEO
5,930,952  common stock
17,742,500 options held and vested
13,475,000  options to vest monthly over 24 month period
2,591,176 Series A Preferred Stock convertible to 25,911,760 common shares
1,739,130 Series B Preferred Stock convertible to 17,391,304 common shares (issuable upon conversion of note dated 3/14/18)
173,913 Series B Preferred Stock convertible to 1,739,130 common shares (issuable upon conversion of note dated 3/19/18)
 29,411,760 Series D-1 Warrants convertible to same in common
8,695,652 Series D-2 Warrants (issuable upon conversion of note)
869,565 Class D-2 Warrants convertible to same in common

Toucan Capital Fund:   804,145 common stock (Linda Powers has voting and dispositive power over)
Toucan Partners, LLC:  2,211,784 common stock (Linda Powers has voting and dispositive power over)

Officer - Les Goldman
172,742 common shares
78,862 exercisable warrants
Plus:  11,526,867 options held and vested
Plus:  8,983,334 options to vest monthly over 24 month period

Officer - Alan Boynton, Ph.D
12,189 common shares
2,481,301 options held and vested
1,063,422 options to vest monthly over 24 month period

Officer - Marnix Bosch, Ph.D., MBA
9,802 common shares
5,930,052 options held and vested
2,481,311 options to vest monthly over 24 month period

Board - Dr. Navid Malik
10,000 common shares
5,099,062 options held and vested
4,343,646 options to vest monthly over 24 month period

Board - Jerry Jasinowski
1,365,031 common shares
652,857 exercisable warrants
2,756,249 options held and vested
2,347,917 options to vest monthly over 24 month period

Cofer Black
964,687 options held and vested
821,771 options to vest monthly over 24 month period

Cognate BioServices:  13,684,294
5,200,865  Series B Preferred convertible to 52,008,650 common shares
58,928,451 exercisable warrants

Outside Ownership of NWBO Common Stock held (9-7-18): 

Woodford Investment Management:   24,815,028

Source:   4/17/18  -- 2017 -- 10K


Highest Share Price after Last Reverse Split:  $12.55 (July 2015)
52-Week High -
 .9799¢
52-Week Low -  .14¢

Smith on Stocks
Larry Smith is a long-time long shareholder, and well-known biotech analys in NWBO and has reported often on the stock.  Some of his more recent analyses can be found below.  His website offers a good deal more analysis.

Northwest Biotherapeutics:  There could be Overwhelming Patient Demand for DCVax-L due to the Right to Try law - June 13, 2018 (Smith on Stocks - Larry Smith)
Northwest Biotherapeutics:  Right to Try Law Potentially Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L - June 3, 2018 (Smith on Stocks - Larry Smith)
Northwest Biotherapeutics:  Right to Try Law Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L - June 3, 2018 (Smith on Stocks - Larry Smith)
Northwest Biotherapeutics:  Blinded Data from Phase 3 Trial Strongly Suggest that DCVax-L is a Major Advance in the Treatment of Newly Diagnosed Glioblastoma Multiforme; It Looks Like NWBO has Hit a Therapeutic and Commercial Home Run - May 30, 2018 (Smith on Stocks - Larry Smith)
Northwest Biotherapeutics: How the Right to Try Remarks in President Trump State of the Union Could Favorably Affect Regulatory Action on DCVax-L and DCVax Direct - February 14, 2018 (Smith on Stocks - Larry Smith)
Northwest Biotherapeutics:  FDA Panel Recommendation to Approve Amgen's Cancer Vaccine is Hugely Significant In Regard to Possible Approval of DCVax-L and DCVax-Direct - May 1, 2015 (Smith on Stocks - Larry Smith)
Northwest Biotherapeutics:  Promising New Data Was Just Presented on DCVax-L in Recurrent Glioblastoma Mulitforme - March 27, 2015 (Smith on Stocks - Larry Smith)
Northwest Biotherapeutics:  How Much Will it Cost to Manufacture DcVax-L - March 5, 2015 (Smith on Stocks - Larry Smith)
The Potentially Key Role of Northwest Biotherapeutics in the Emerging Immuno-Oncology - February 3, 2105 (Smith on Stocks - Larry Smith)
Notes from Linda Powers Presentation in San Francisco - January 12, 2015 (Smith on Stocks - Larry Smith)
Current Investment Recommendations for Stocks Covered by SmithOnStocks; A Yearend Review - December 19, 2014 (Smith on Stocks - Larry Smith)
NWBO discussed at great length.
NWBO:  Putting Recent Clinical Data on DCVax Direct in Perspective - November 28, 2014 (Smith on Stocks - Larry Smith)

U.K. May Grant Early Patient Access for DCVax-L Priot to Formal Approval  - September 18, 2014 (Seeking Alpha - Larry Smith [Smith on Stocks])
Exciting News on Potential for Early Patient Access for DCVax-L in the UK - September 17, 2014 
(Larry Smith, Smith on Stocks)
The Data Monitoring Commitee Addresses the Status of the DCVax-L Trial - August 13, 2014 (Seeking Alpha - Larry Smith [Smith on Stocks])


Smith on Stocks - Short Report Series
Part 1 in a Series of Reports on Blatant, Widespread Stock Manipulation that is Enabled by Illegal, Naked Shorting - Larry Smith, March 27, 2019
Part 2 in Series on Illegal Naked Shorting’s Role in Stock Manipulation- Conventional Wisdom on How Short Sales are Executed 
- Larry Smith, April 4, 2019
Part 3 in Series on Illegal Naked Shorting’s Role in Stock Manipulation – Prime Brokers and the DTCC Have a Troubling Monopoly on Clearing and Settling Stock Trades- Larry Smith, April 11, 2019
Part 4 in Series on Illegal Naked Shorting’s Role in Stock Manipulation: Who are the Key Players?- Larry Smith, April 4, 2019

Transfer Agent 
Computershare Trust Company, N.A.

P.O. Box 30170, College Station, Texas  77842
Monday through Friday. Call (866) 282-9695.

UCLA Department of Neurology
UCLA Chair of Neurosurgery Linda Liau, PhD - Welcome Letter
DCVax in 4th paragraph - "on the road to FDA approval"

A Personal Quest to Cure Brain Cancer - (Into The Brain and Beyond by UCLA Neurosurgery)

UCLA Trials relating to Dendritic Cells
Vaccine Therapy in Treating Patients with Malignant Glioma NCT00612001
Vaccine Therapy in Treating Young Patients Who are Undergoing Surgery for Malignant Glioma NCT00107185
Vaccine Therapy in Treating Patients with Malignant Glioma NCT00068510
Vaccine Therapy in Treating Patients with Stage IV or Relapsed Malignant Melanoma NCT00005617
Autologous Dendritic Cells in Treating Patients with Metastatic Kidney Cancer NCT01826877
Vaccine Therapy in Treating Patients who are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-SMall Cell Lung Cancer NCT00098917
Vaccine for Patients with Newly Diagnosed or Recurrent Low-Grade Glioma NCT01635283
Dendritic Cell Vaccine for Ptients with Brain Tumors NCT01204684
Abstract to NCT01204684 - ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION
Vaccine Therapy in Treating Patients with Unresected Stage III or Stage IV Melanoma NCT00107159
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients with Locally Advanced or Mestastatic Malignancies NCT02070406

Upcoming Events
World Vaccine Congress - April 16, 2019 - 12:40 p.m. ET (Washington DC) - "DCVax® Personalized Immune Therapies for Cancer" - Linda Powers, CEO, NWBO



Videos
Linda Liau, M..D., UCLA - Immunotherapy and Clinical Trials for Brain Tumors • UCLA Neurosurgery - March 30, 2019, published on Aprl 30, 2019
Transcription of Linda Liau's presentation - posted by sentiment stocks, May 6, 2019, with transcription help provided by i-hub poster longfellow95
"I Love What I Do" - Internationally Renowned Brain Surgeon Dr. Linda Liau - April 10, 2019 / Spectrum News 1 video
Robert Prins, MD - The Future of Vaccine Treatment in Brain Cancer - March 28, 2016, Seattle Science Foundation - video removed
    Partial Transcript of Prins' Presentation
Linda Liau, MD - Immunotherapies for GBM:  Tumor Vaccines by Linda Liau, M.D., Ph.D., M.B.A. - December 15, 2016, Seattle Science Foundation
  Transcription of Linda Liau's presentation - December 15, 2016, Seattle Science Foundation - posted by sentiment stocks, November 16, 2018
Could our own bodies hold the key to curing cancer? - Fox News with Dr. Marc Siegel and Martha MacCallum- aired November 7, 2013

Webcasts
ASCO 2018 - Discussion of Published Interim Data on Blended Population for the Phase 3 Trial of DCVax-L for Newly Diagnosed brain Cancer - June 3, 2018
   Transcription of ASCO 2018 video - posted by sentiment_stocks 7/12/18
ASCO 2015 - Overview of DCVax Direct Phase 1 Trial - May 30, 2015 - Webcast by Marnix L. Bosch, MBA, PhD, CTO, NWBO (YouTube)
   Slides presented in ASCO presentation to accompany Video
  Partial Transcription of Dr. Bosch Video
NWBO Presentation at ITOC2 Conference - March 26, 2015 - Webcast by Marnix L. Bosch, MBA, PhD, CTO, NWBO (YouTube)
NWBO Presentation at Phacilitate Immunotherapy World 2015 - January 26, 2015 - Webcast by Linda Powers (YouTube)
  Transcript of Biotech Showcase 2015 - from January 12, 2015 - provided by sentiment_stocks
NWBO- 25th Annual Oppenheimer Healthcare Conference - December 10, 2014 - accompanying Slide Show
  Transcript of 25th Annual Oppenheimer Healthcare Conference - provided by RK (Includes Q&A at the end)
NWBO Linda Powers Presents at SMi 3rd Cancer Vaccines Conference 2014 - Linda announces England's 1st PIM (Promising Innovative Medicine) Designation and Recent Progress to Date and offers an excellent explanation of how DCVax works

Websites
NWBO Company Website
Wiki page for NWBO
Informative Investor Website
Immunology Acronyms

NWBO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NWBO News: Quarterly Report (10-q) 05/10/2019 05:24:36 PM
NWBO News: Annual Report (10-k) 04/02/2019 05:23:33 PM
NWBO News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 03/19/2019 05:19:39 PM
NWBO News: Amended Statement of Ownership (sc 13g/a) 02/14/2019 03:33:33 PM
NWBO News: Amended Statement of Ownership (sc 13g/a) 02/14/2019 03:20:35 PM
PostSubject
#224783  Sticky Note Hungary hippo... the treatment involved with NWBO is sentiment_stocks 04/30/19 02:17:09 PM
#221395  Sticky Note Been 7 months since this brilliant post from abc1212 04/04/19 06:01:38 AM
#209649  Sticky Note Final Questions to be sent to Management IkeEsq 01/23/19 04:09:07 PM
#197542  Sticky Note (PRN) Bigger Capital and District 2 Capital Issue tctrader38 11/15/18 08:31:26 AM
#182347  Sticky Note ASCO 2018 Presentation for DCVax-L - Sunday, June sentiment_stocks 07/12/18 10:15:05 PM
#44577  Sticky Note Ummm, have any of you people ever read IH Admin [Shelly] 11/08/15 07:37:32 PM
#39690  Sticky Note The topic to be discussed here is NWBO. IH Dan (Retired) 08/31/15 12:21:09 PM
#227941   Good Luck to all long in NWBO. Kam8 05/19/19 02:06:39 AM
#227940   Lots of people dishing mixes of information with biosectinvestor 05/19/19 01:55:12 AM
#227939   You’re not talking about direct sales of shares biosectinvestor 05/19/19 01:50:15 AM
#227938   Fever dreams and fantasies are always interesting to biosectinvestor 05/19/19 01:42:21 AM
#227937   I couldn't find any information to show that Dr Bala 05/19/19 01:41:38 AM
#227936   That's so true, not everyone has Bigger Capital money. survivor1x 05/19/19 12:57:17 AM
#227935   The sense I get is it could be MasterBlastr 05/19/19 12:37:32 AM
#227934   True, but at that point the company is Poor Man - 05/18/19 10:59:37 PM
#227933   Revised Matrix abeta 05/18/19 10:46:15 PM
#227932   They had already resolved and remedied the most sentiment_stocks 05/18/19 10:35:57 PM
#227931   Ex, I have no idea what you are flipper44 05/18/19 10:32:29 PM
#227930   The cost alone could likely keep someone from sentiment_stocks 05/18/19 10:31:26 PM
#227929   There is more to this story that Poor Man - 05/18/19 10:24:22 PM
#227928   flipper44, Right. What I was thinking about the Doc logic 05/18/19 10:07:43 PM
#227927   Bingo. Even if some crazy issues arise survivor1x 05/18/19 09:27:37 PM
#227926   https://www.youtube.com/watch?v=slmilObZl28 While I doubt the helmet hurts so survivor1x 05/18/19 09:24:46 PM
#227925   I also suspect that the capital raises at sentiment_stocks 05/18/19 07:58:42 PM
#227924   OK will repost tomorrow abeta 05/18/19 07:49:45 PM
#227923   bullzeye gropgrip 05/18/19 07:49:03 PM
#227922   Abeta, In 2012 the trial size had been increased Lykiri 05/18/19 07:30:35 PM
#227921   However exactly you meant that, it was funny. exwannabe 05/18/19 06:57:55 PM
#227920   “Objective response rate correlates poorly with overall survival” Is rogers5729 05/18/19 06:28:08 PM
#227919   The planned number of subjects to be included Lykiri 05/18/19 05:41:33 PM
#227918   F.4.1 In the member state: 24 abeta 05/18/19 05:36:46 PM
#227917   abeta, Thank you! Lykiri 05/18/19 05:09:15 PM
#227916   The T-Trades are executed during normal trading hours, Poor Man - 05/18/19 04:11:02 PM
#227915   Sentiment: and was told that the trade took maverick_1 05/18/19 04:09:48 PM
#227914   Hypothetical Matrix of the Trial abeta 05/18/19 03:48:36 PM
#227913   Form T trades are defined as trades that sentiment_stocks 05/18/19 03:41:57 PM
#227912   Yes. I do not know when the FDA started exwannabe 05/18/19 03:29:49 PM
#227911   [Yep, if you shoot a handgun at a maverick_1 05/18/19 03:27:52 PM
#227910   Was it common that approval would be based sentiment_stocks 05/18/19 03:14:39 PM
#227909   Yes exactly... perfect time in just a matter erik007tc 05/18/19 03:04:21 PM
#227908   Dark Pools, Naked Shorts, Deep States and UFOs. Poor Man - 05/18/19 02:53:11 PM
#227907   Longfellow: maverick_1 05/18/19 02:35:10 PM
#227906   What is your point? Lykiri 05/18/19 02:23:42 PM
#227905   What is your point? exwannabe 05/18/19 02:12:58 PM
#227904   She once had something like 70% after the Lykiri 05/18/19 01:45:25 PM
#227903   No Surgery Advantage for unMETH abeta 05/18/19 01:38:15 PM
#227902   Why did she sell off 80% or so longfellow95 05/18/19 01:25:00 PM
#227901   You and longfellow miss the point or are longfellow95 05/18/19 01:22:16 PM
#227900   She may not even give away 20% of exwannabe 05/18/19 01:09:52 PM
#227899   “Until we reach data lock, the data will sentiment_stocks 05/18/19 01:09:47 PM
#227898   Mars, here we go again stating your opinion as Al4door 05/18/19 01:03:13 PM
#227897   You and longfellow miss the point or are deflecting exwannabe 05/18/19 01:02:20 PM
#227896   Oh yes I got idea LP could start carp77 05/18/19 12:58:55 PM
#227895   You will get many replies talking about FDA longfellow95 05/18/19 12:52:12 PM
#227894   Objective response rate correlates poorly with overall survival flipper44 05/18/19 12:46:21 PM
#227893   LP's husband is a billionaire. She may not marzan 05/18/19 12:42:42 PM
#227892   Prior to Yescara, R/R DLBCL patients had a jondoeuk 05/18/19 12:32:17 PM
PostSubject